09:47 AM EST, 11/13/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) and Exscientia ( EXAI ) said Wednesday that their respective shareholders have approved their proposed combination.
The deal is expected to be completed Nov. 20, the companies said.
Shares of Recursion rose 1.9% and Exscientia ( EXAI ) climbed 2% in recent trading.
Price: 7.77, Change: +0.19, Percent Change: +2.51